Last mentioned: Mar 26, 2026
Q1 Guidance
Precigen forecasts $18M+ revenue for Q1 2026, a massive sequential jump.
Albumin Commercialization
Dyadic and ProLiant Health launch recombinant albumin for global sales.
FY 2025 Close
Dyadic ends year with $8.6M cash; Paysign hits record $82M annual revenue.
Papzimius Launch
Precigen initiates commercial shipments of Papzimius for adult RRP.
Dyadic and Precigen have successfully transitioned from R&D-focused entities to commercial-stage biotechs, marked by the launch of recombinant albumin and Papzimius respectively. This shift is supported by a robust pharma services sector, as evidenced by Paysign’s record growth in patient affordability programs for top-tier manufacturers.
This page surfaces every story mentioning Paysign across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Paysign was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |